Articoli con mandati relativi all'accesso pubblico - Eyad ElkordUlteriori informazioni
Non disponibili pubblicamente: 3
Clinical and immunologic results of a phase II trial of sequential imiquimod and photodynamic therapy for vulval intraepithelial neoplasia
U Winters, S Daayana, JT Lear, AE Tomlinson, E Elkord, PL Stern, ...
Clinical Cancer Research 14 (16), 5292-5299, 2008
Mandati: Cancer Research UK
An MVA-based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases
E Elkord, A Dangoor, NL Drury, R Harrop, DJ Burt, JW Drijfhout, C Hamer, ...
Journal of Immunotherapy 31 (9), 820-829, 2008
Mandati: Cancer Research UK
Immunotherapy for gastrointestinal cancer: current status and strategies for improving efficacy
E Elkord, RE Hawkins, PL Stern
Expert Opinion on Biological Therapy 8 (4), 385-395, 2008
Mandati: Cancer Research UK
Disponibili pubblicamente: 17
Immune evasion in cancer: Mechanistic basis and therapeutic strategies
DS Vinay, EP Ryan, G Pawelec, WH Talib, J Stagg, E Elkord, T Lichtor, ...
Seminars in cancer biology 35, S185-S198, 2015
Mandati: Cancer Research UK
Designing a broad-spectrum integrative approach for cancer prevention and treatment
KI Block, C Gyllenhaal, L Lowe, A Amedei, ARMR Amin, A Amin, ...
Seminars in cancer biology 35, S276-S304, 2015
Mandati: US National Institutes of Health, US Department of Veterans Affairs …
Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma
C Ralph, E Elkord, DJ Burt, JF O'Dwyer, EB Austin, PL Stern, RE Hawkins, ...
Clinical Cancer Research 16 (5), 1662-1672, 2010
Mandati: Cancer Research UK
Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia
S Daayana, E Elkord, U Winters, M Pawlita, R Roden, PL Stern, ...
British journal of cancer 102 (7), 1129-1136, 2010
Mandati: US National Institutes of Health, Cancer Research UK
Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival
RW Griffiths, E Elkord, DE Gilham, V Ramani, N Clarke, PL Stern, ...
Cancer Immunology, Immunotherapy 56, 1743-1753, 2007
Mandati: Cancer Research UK
Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells
S Khan, DJ Burt, C Ralph, FC Thistlethwaite, RE Hawkins, E Elkord
Clinical Immunology 138 (1), 85-96, 2011
Mandati: Cancer Research UK
Regulatory T cell subsets in filarial infection and their function
S Metenou, TB Nutman
Frontiers in immunology 4, 305, 2013
Mandati: US National Institutes of Health
Expanded subpopulation of FoxP3+ T regulatory cells in renal cell carcinoma co-express Helios, indicating they could be derived from natural but not induced Tregs
E Elkord, S Sharma, DJ Burt, RE Hawkins
Clinical immunology 140 (3), 218-222, 2011
Mandati: Cancer Research UK
T Cell–Based Immunotherapy of Metastatic Renal Cell Carcinoma: Modest Success and Future Perspective
A Shablak, RE Hawkins, DG Rothwell, E Elkord
Clinical Cancer Research 15 (21), 6503-6510, 2009
Mandati: Cancer Research UK
5T4 oncofetal antigen is expressed in high risk of relapse childhood pre-B acute lymphoblastic leukemia and is associated with a more invasive and chemotactic phenotype
FV Castro, OJ McGinn, S Krishnan, G Marinov, J Li, AJ Rutkowski, ...
Leukemia 26 (7), 1487-1498, 2012
Mandati: Cancer Research UK
A broad-spectrum integrative design for cancer prevention and therapy
KI Block, C Gyllenhaal, L Lowe, A Amedei, ARMR Amin, A Amin, ...
Seminars in cancer biology 35 (Suppl), S276, 2015
Mandati: US National Institutes of Health, Swedish Research Council, Breast Cancer …
Adoptive transfer of Treg depleted autologous T cells in advanced renal cell carcinoma
FC Thistlethwaite, E Elkord, RW Griffiths, DJ Burt, AM Shablak, ...
Cancer Immunology, Immunotherapy 57, 623-634, 2008
Mandati: Cancer Research UK
Combining FoxP3 and Helios with GARP/LAP markers can identify expanded Treg subsets in cancer patients
M Abd Al Samid, B Chaudhary, YS Khaled, BJ Ammori, E Elkord
Oncotarget 7 (12), 14083-14094, 2016
Mandati: UK Medical Research Council, National Institute for Health Research, UK
Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4)
E Elkord, A Dangoor, DJ Burt, TD Southgate, S Daayana, R Harrop, ...
Cancer immunology, immunotherapy 58, 1657-1667, 2009
Mandati: Cancer Research UK
CD4+ T-cell recognition of human 5T4 oncofoetal antigen: implications for initial depletion of CD25+ T cells
E Elkord, DJ Burt, JW Drijfhout, RE Hawkins, PL Stern
Cancer Immunology, Immunotherapy 57, 833-847, 2008
Mandati: Cancer Research UK
5T4 as a target for immunotherapy in renal cell carcinoma
E Elkord, A Shablak, PL Stern, RE Hawkins
Expert Review of Anticancer Therapy 9 (12), 1705-1709, 2009
Mandati: Cancer Research UK
Temporal patterns of cancer burden in Asia, 1990–2019: a systematic examination for the Global Burden of Disease 2019 study
R Sharma, H Abbastabar, DM Abdulah, H Abidi, H Abolhassani, ...
The Lancet Regional Health-Southeast Asia 21, 2024
Mandati: Bill & Melinda Gates Foundation, Wellcome Trust/DBT India Alliance
Le informazioni sulla pubblicazione e sul finanziamento vengono stabilite automaticamente da un software